Name | NCT-505 |
Description | NCT-505 is a potent and selective inhibitor of aldehyde dehydrogenase (ALDH1A1, IC50 = 7 nM) and a weak inhibitor of hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 with IC50 values of >57 μM, 22.8 μM, 20.1 μM, and >57 μM, respectively. |
In vitro | NCT-505 (compound 86) is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor with IC50 of 7 nM, weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM ). NCT-505 has no significant inhibitory effect on 5-hydroxyprostaglandin dehydrogenase (HPGD) and type 4 hydroxysteroid dehydrogenase (HSD17β4) (IC50, >57 μM). In addition, NCT-505 showed potent cellular viability, reducing the viability of OV-90 cells with EC50 of 2.10-3.92 μM. NCT-505 is also cytotoxic to SKOV-3-TR cells with IC50 of 1, 3, 10, 20, 30 μM in titration analysis[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/ml (105.44 mM)
|
Keywords | NCT-505 | NCT505 | NCT 505 | Inhibitor | inhibit | Aldehyde Dehydrogenase (ALDH) |
Inhibitors Related | Disulfiram | Methotrexate | ALDH1A3-IN-3 | Rotenone | Mycophenolate Mofetil | Ribavirin | 4-Diethylaminobenzaldehyde | Benzyl alcohol | Isomalt | Isoniazid | Sodium Oxamate | Ivosidenib |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Anti-Parkinson's Disease Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | Metabolism Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library |